Abstract Library

#4594 RNA splicing as a key regulatory player with translational potential in pulmonary neuroendocrine neoplasms (lungNETs)

Introduction: Neuroendocrine tumours (NETs) are a diverse group of neoplasms arising from neuroendocrine cells. Within this group, lung neuroendocrine tumours (LungNETs) represent one of the most frequent subtypes of NETs. LungNETs are classified by grade, according to their proliferative index and aggressiveness. Among them, typical carcinoids (G1) and atypical carcinoids (G2) are the lowest grade subtypes. While these tumours are less aggressive, they remain underexplored compared to higher-grade subtypes, highlighting the need for molecular studies to improve clinical approaches. In this context, previous studies have shown that abnormalities in the splicing machinery are frequent in tumour pathologies and also occur in LungNETs.

Conference:

Presenting Author:

Authors: Gutiérrez Camacho L, Ruiz-Palacios D, García Vioque V, González-Pérez C, Moreno Montilla M,

Keywords: splicing, neuroendocrine tumour, Lung NET, typical carcinoid, atypical carcinoid,

#4559 Exploring the interplay between RNA methylation and splicing dysregulation in neuroendocrine tumours

Introduction: Post-transcriptional modifications play crucial roles in regulating gene expression and cellular function. While recent findings indicate that alternative splicing dysregulation plays a key role in tumorigenic properties of neuroendocrine tumours (NETs), the role of other RNA processing mechanisms, such as N6-methyladenosine (m6A) — being the most common RNA methylation — remains largely unexplored in NETs.

Conference:

Presenting Author:

Authors: Ruiz-Palacios D, Gutiérrez Camacho L, García Vioque V, Moreno Montilla M, Blázquez-Encinas R,

Keywords: RNA methylation, splicing, neuroendocrine tumour, lung NET, pan NET,

#4414 Impact of chromogranin A expression on clinicopathological characteristics and prognosis in patients with gastrointestinal tumours exhibiting neuroendocrine differentiation

Introduction: Pathological diagnosis of neuroendocrine differentiation (NED) relies on histomorphological assessment and specific markers, including chromogranin A (CgA) and synaptophysin (Syn). Previous studies indicate that tumours with a high proportion of CgA (+) exhibit increased malignancy and aggressiveness in neuroendocrine tumours, suggesting that CgA may serve as a prognostic marker.

Conference:

Presenting Author: Liang T

Authors: Wang W, Jiang K, Liu X, Zhao L, Yu Z,

Keywords: neuroendocrine differentiation, gastric cancer, colorectal cancer, chromogranin A,

#4330 Clinical and gut microbiota (GM) markers of aggressive carcinoid syndrome (CS)

Introduction: While most patients (pts) with CS present indolent disease (iCS), others have aggressive disease (aCS). Little is known about biomarkers of aCS.

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Henrique K, Durant L, Iebba V, Derosa L,

Keywords: neuroendocrine tumour, carcinoid syndrome, gut microbiome,

#4318 Management of asymptomatic, sporadic, small non-functional pancreatic neuroendocrine tumours: Active surveillance or surgery? A retrospective cohort study in the SEER database

Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) exhibit a wide heterogeneity of aggressiveness and optimal management of asymptomatic, sporadic, small PanNETs remains controversial.

Conference:

Presenting Author: Chen C

Authors: Chen C, Zheng Z, Li P, Hu H,

Keywords: Pancreatic neuroendocrine tumour, surveillance, surgery, prognosis, SEER,